Dr. Leena Gandhi currently serves as Vice President, Immuno-Oncology Development at Eli Lilly. She previously was an associate professor of medicine at NYU Perlmutter Cancer Center where she served as Director of Thoracic Medical Oncology from 2016-2018 and prior to that she worked as a thoracic oncologist in the Early Drug Development Center at Dana-Farber Cancer Institute. Her focus of research has been on novel therapeutics in lung cancer with a focus on immuno-oncology and biomarkers of immunotherapy response in lung cancer as well as modulation of the immune microenvironment by chemotherapies and other therapies. She was a lead investigator in defining PD-L1 biomarkers used for pembrolizumab therapy in NSCLC.